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DObjective: Despite growing awareness of the clinical significance of atrial fibrillation (AF) and observational
data demonstrating the safety and efficacy of surgical therapy, AF ablation is variably performed among patients
with AF undergoing cardiac surgery.We examined the national trends of surgical ablation and perioperative out-
comes for stand-alone surgical ablation of AF.
Methods: Using the Society of Thoracic Surgeons Adult Cardiac Surgery Database, 91,801 (2005-2010) surgical
AF ablations were performed of which 4893 (5.3%) were stand-alone procedures. The outcomes of 854
propensity-matched pairs having ‘‘on’’ versus ‘‘off’’ cardiopulmonary bypass stand-alone ablationwere compared.
Results: The percentage of patients with preoperative AF increased from 2005 to 2010 (from 10.0% to 12.2%).
Overall, 40.6% of patients with AF underwent concomitant surgical ablation—a significant decline of 1.6%
from 2005 to 2010. The number of stand-alone surgical ablations increased significantly from 552 to 1041 cases
(2005-2010). Overall, the stand-alone group had a mean age of 60 years, 71% were men, and 80% were treated
‘‘off’’ cardiopulmonary bypass. The ‘‘on’’ cardiopulmonary bypass group had significantly more pulmonary
disease, diabetes, and congestive heart failure. Overall, the operative mortality and stroke rate was 0.7% for
each. After propensity matching, the ‘‘off’’ cardiopulmonary bypass group underwent significantly fewer reop-
erations for bleeding and had a lower incidence of prolonged ventilation and shorter hospitalization. New pace-
maker implantation was low, without group differences.
Conclusions: The prevalence of AF in patients undergoing cardiac surgery has increased, as has the number of
stand-alone surgical ablations. The treatment of concomitant disease declined slightly. Isolated surgical ablation
is safe, performed ‘‘on’’ or ‘‘off’’ cardiopulmonary bypass. These results support consideration of surgical AF
ablation as an alternative to percutaneous ablation for patients with lone AF. (J Thorac Cardiovasc Surg
2012;144:1051-60)Earn CME credits at
http://cme.ctsnetjournals.org
The surgical treatment of atrial fibrillation (AF), whether as
a stand-alone procedure or concomitantly with another car-
diac procedure has been performed for more than 2 de-
cades.1 The recent introduction of newer surgical ablation
devices has resulted in significant expansion of the number
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The Journal of Thoracic and Carto the technical ease and speed of application.2,3 Despite
a growing awareness of the clinical significance of AF,
along with several prospective and observational studies
demonstrating the safety and efficacy of surgical ablation
early and late after surgery, AF ablation remains variably
performed among patients with AF undergoing cardiac
surgery.2,4-7 Using the Society of Thoracic Surgeons (STS)
Adult Cardiac Surgery Database (ACSD), we sought to
assess the national trends for concomitant surgical ablation
of AF for elective, urgent, and nonreoperative cardiac
surgery patients and the perioperative clinical outcomes
for patients undergoing stand-alone surgical ablation proce-
dures for lone AF with or without the use of cardiopulmo-
nary bypass (CPB).
METHODS
Data Source
The STS has maintained a prospective database of patients undergoing
cardiothoracic surgery in the United States since 1987. Harvested data are
maintained and analyzed by the Duke Clinical Research Institute in compli-
ance with the Health Insurance Portability and Accountability Act of 1996.
Variables are collected on a standardized data form that includes information
about patient demographics, medical history, surgical procedures, and out-
come (available from: http://www.ctsnet.org/file/ThoracicDCFV2_07_
Nonannotated.pdf). In the present study, we used data from the STS ACSDdiovascular Surgery c Volume 144, Number 5 1051
Abbreviations and Acronyms
ACSD ¼ Adult Cardiac Surgery Database
AF ¼ atrial fibrillation
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
CPB ¼ cardiopulmonary bypass
HRS ¼ Heart Rhythm Society
ISMICS ¼ International Society for Minimally
Cardiothoracic Surgery
MVR ¼ mitral valve repair
STS ¼ Society of Thoracic Surgeons
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Dto report on surgical ablation procedures for AF performed as an isolated pro-
cedure or concomitantly with other cardiac surgical procedures from 2005 to
2010. Data related to the specific lesion set and ablative technologywere var-
iably collected owing to changes in device technology; therefore, this infor-
mation was not included in the present report. The new ‘‘Surgical Ablation
for Atrial Fibrillation’’ module developed by the STS will theoretically
improve the ability to collect meaningful data related to the lesion set and
ablative technology (available from: http://www.sts.org/news/sts-atrial-
fibrillation-module-now-available).
The type of analyses presented in this report have been reviewed and ap-
proved by the Duke University Health System institutional review board
under protocol number CR1_Pro00005876.
Study Population
The study population included patients who had undergone surgical ab-
lation for AF either as a stand-alone procedure or concomitantly with other
cardiac procedures at STS-participating hospitals between January 1, 2005
and December 31, 2010. Patients were excluded if they met any of the fol-
lowing criteria: missing data regarding CPB status, history of coronary ar-
tery bypass grafting (CABG), valve, or other cardiac operation, and
emergent or emergent salvage status.
Statistical Analysis
The distribution of patient characteristics and outcomes was summa-
rized using the median or mean and interquartile range (25th to 75th per-
centile) for continuous variables and the percentage distribution for
categorical variables. Comparisons of subgroups were performed using
Wilcoxon rank sum tests (continuous variables) or c2 tests (categorical
variables).
Propensity scores of CPB usage were estimated using a logistic model
that included the following variables: age modeled as linear spline with
knots at 50 and 60, gender, body surface area modeled as quadratic poly-
nomial separately for men and women, ejection fraction truncated between
10% and 50%, nonwhite race, dialysis, cardiogenic shock, hypertension,
immunosuppressive treatment, percutaneous coronary intervention within
6 hours, preoperative intra-aortic balloon pump or inotropes, peripheral
vascular disease, unstable angina (no myocardial infarction<7 days), left
main disease, preoperative symptomatic AF within 2 weeks of surgery,
AF correction surgery modeled as a standard surgical maze procedure or
a combination of standard and other procedure versus other surgical abla-
tive procedure, cerebrovascular disease or cerebrovascular accident,
chronic lung disease, diabetes, number of diseased vessels, timing of myo-
cardial infarction, operative status (elective vs urgent), congestive heart
failure, and New York Heart Association class. Missing values were im-
puted to the most frequent values. Patients were then matched using
a Greedy 5 to 1 digit matching algorithm. Standardized differences were
used to assess significance in differences of preoperative variables between1052 The Journal of Thoracic and Cardiovascular Surthe 2 groups (‘‘on pump’’ vs ‘‘off pump’’). A standardized difference was
used, rather than a P value, because it has been shown by others to not be
sensitive to the sample size, as the P value is, and hence better for evalua-
tion of propensity matching.
After propensity matching, the postoperative outcomes of the on-CPB
and off-CPB groups were compared using McNemar tests (matched com-
parison) for binary outcomes and Wilcoxon signed-rank tests for continu-
ous outcomes. P values were not adjusted for multiple comparisons.
Analysis was performed using SAS, version 9.1 (SAS Institute, Cary, NC).
RESULTS
Concomitant Surgical Ablation Procedures for AF
Of the patients undergoing elective or urgent nonredo
cardiac surgery in North America during the study period,
11% (n ¼ 153,239) presented with a history of AF, and
62,152 surgical ablations for concomitant AF were per-
formed (Figure 1). The frequency of concomitant surgical
ablations performed between 2005 and 2010 was 40.6%
(Figure 1)and declined during the study period. CABG pa-
tients had the lowest incidence of preoperative AF (6.5%)
and those undergoing mitral valve repair (MVR) the great-
est (29%). A steady increase in the number of surgical ab-
lation procedures performed annually was documented,
with a total of 8461 procedures in 2005 and 11,363 proce-
dures in 2010. However, the overall number of patients pre-
senting for cardiac surgery with AF also increased from
20,878 patients in 2005 to 29,202 patients in 2010
(Figure 1).
An interesting trend in concomitant surgical ablation
was identified when the percentage of patients with AF
treated was assessed by the type of concomitant procedure
(Figure 2 and Table 1). On average, 61.5% of patients
with preoperative AF undergoing MVR underwent abla-
tion compared with only 27.5% of patients undergoing
CABG. Patients undergoing isolated aortic valve replace-
ment (AVR) with AF underwent ablation 33.9% of the
time. The effect of MVR on the rate of surgical ablation
was also documented when analyzing the concomitant
CABG plus AVR group of patients. This revealed that
the combined AVRþCABG patients with AF underwent
surgically ablation on average only 32.1% of the time
and the combined CABGþMVR underwent surgically ab-
lation on average 51.8% of the time. Detailed data regard-
ing the incidence of AF ablation stratified by year is listed
in Table 1.
Stand-Alone Surgical Ablation Procedures
Demographic data for the group of patients undergoing
stand-alone procedures is presented in Table 2. The total
of number of stand-alone surgical ablation procedures
performed in 375 centers between 2005 and 2010 was
4893. Throughout the study period, the number of
stand-alone procedures performed annually almost dou-
bled, from 552 procedures in 2005 to 1014 cases in
2010, using both on- and off-CPB strategies. A total ofgery c November 2012
FIGURE 1. Frequency of preoperative (Preop) atrial fibrillation (AF) and surgical ablation for AF procedures among patients undergoing primary non-
emergent cardiac surgery.
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D4449 elective or urgent, nonredo stand-alone procedures
were performed, of which 876 (20%) were performed
with CPB and 3573 (80%) were performed without
CPB. Differences between groups stratified by CPB sta-
tus are presented in Table 3. The on-CPB group had a sig-
nificantly greater body mass index, incidence of diabetes
mellitus (insulin and noninsulin dependent), history of
smoking, chronic obstructive pulmonary disease, conges-
tive heart failure, and cerebrovascular disease. Patients inFIGURE 2. Concomitant surgical ablation for atrial fibrillation (AF) by type
grafting; AVR, aortic valve replacement; MV, mitral valve; Other, left ventric
repair, batista, surgical ventricular restoration, congenital defect repair, transmy
aneurysm, other.
The Journal of Thoracic and Carthe on-CPB group underwent urgent surgery at a rate of
5.94% versus 0.73% for the off-CPB group (P<.0001),
and the ejection fraction was significantly greater in the
off-CPB group (52.75% vs 55.59%, P< .0001).
The uncorrected outcomes after stand-alone surgical
ablation are presented in Table 3. The overall operative
mortality (30 days) was 0.74% (off-CPB group, 0.5%;
on-CPB group, 1.7%; P¼ .7). The rate of any STS compli-
cation was 16.43%, with significantly greater rates for theof concomitant procedure. Preop, Preoperative; CABG, coronary bypass
ular aneurysm repair, ventricular septal defect repair, atrial septal defect
ocardial laser revascularization, cardiac trauma, cardiac transplant, aortic
diovascular Surgery c Volume 144, Number 5 1053
TABLE 1. Percentage of concomitant surgical ablation for atrial
fibrillation performed for different concomitant procedure types
Concomitant
procedure
2005
(%)
2006
(%)
2007
(%)
2008
(%)
2009
(%)
2010
(%)
CABG 26 30 28 28 27 26
AVR 33 36 36 35 34 31
MVR 61 64 62 62 60 60
CABGþAVR 32 34 36 33 30 30
CABGþMV 54 53 52 51 50 51
Other 55 57 55 51 49 50
CABG, Coronary bypass grafting; AVR, aortic valve replacement;MVR, mitral valve
repair; Other, left ventricular aneurysm repair, ventricular septal defect repair, atrial
septal defect repair, batista, surgical ventricular restoration, congenital defect repair,
transmyocardial laser revascularization, cardiac trauma, cardiac transplant, aortic
aneurysm, other.
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Don-CPB group (27.97% vs 13.60%, P<.0001). The overall
stroke rate was 0.72%, with a significantly greater inci-
dence for the on-CPB group at 1.26% (P¼ .017). The renal
failure rates were greater for the on-CPB group, with an
overall incidence of 2.45% (5.48% vs 1.71%;
P ¼ .0001). The incidence of blood transfusion was greater
for the on-CPB group at 17.6% (vs 3.1% off-CPB,TABLE 2. Patient demographics and risk factors
Variable Overall (n ¼ 4449)
Demographics
Agey (y)
Mean 60.42
IQR 54-68
Men 71.00
Risk factors
Weight (kg)y
Mean 96.46
IQR 81.55-109.00
Body surface areay (m2)
Mean 2.12
IQR 1.95-2.3
Smoker (any form of past tobacco use) 23.51
Preoperative AF 91.71
Diabetes mellitus 14.46
Renal failure 0.65
Preoperative dialysis 0.34
Hypertension 61.18
Chronic lung disease/COPD 12.29
Peripheral vascular disease 3.28
Cerebrovascular disease 10.90
Preoperative MI within 21 d 0.22
Preoperative CHF 9.69
CHF-NYHA class 4 0.63
Ejection fractiony
Mean 54.94
IQR 50-60
Urgent procedure status 1.75
Data presented as mean and IQR or percentages. CPB, Cardiopulmonary bypass; IQR, inte
MI, myocardial infarction; CHF, congestive heart failure; NYHA, New York Heart Associat
ables. yP values based on stratum-adjusted c2 rank-based group mean score statistics for
1054 The Journal of Thoracic and Cardiovascular SurP<.001). The median hospital stay was 6 days in the on-
CPB group and 4 days in the off-CPB group (P<.0001).
The newly implanted pacemaker rate was similar for both
groups, with an overall rate of 1% (P ¼ .1686).
After the identification of 854matched pairs, a propensity
analysis was performed (n ¼ 1708; Table 4 and Figures 3
and 4). The perioperative results for the matched-group
patients demonstrated no significant differences between
the groups for all major outcomes, except for prolonged
intubation (>24 hours; 6.56% vs 3.98% for on-CPB and
off-CPB groups, respectively; P ¼ .014) and reoperation
for bleeding (2.2% vs 0.35% for on-CPB and off-CPB
group, respectively; P ¼ .0003). The median length of
stay remained significantly longer for the on-CPB group
than for the off-CPB in the matched population (6 vs
4 days, respectively; P<.001) (Table 5).
DISCUSSION
In the present study, data from the STSACSDwas used to
describe contemporary practice of surgical AF ablation in
North America between 2005 and 2010. The data included
surgical ablation performed as a stand-alone procedure orOn-CPB (n ¼ 876) Off-CPB (n ¼ 3573) P value*
.4074
59.42 60.67
53-67 54-68
71.92 70.78 .1924
.0009
98.65 95.93
83-113 81-108.6
.0036
2.14 2.12
1.96-2.32 1.94-2.29
24.66 23.23 .0419
89.73 92.19 .7363
17.94 13.61 .0056
0.68 0.64 .5504
0.34 0.34 .6151
62.21 60.93 .1200
16.78 11.20 .0242
4.00 3.11 .2303
13.36 10.30 .5950
0.68 0.11 .0174
19.86 7.19 <.0001
1.48 0.42 <.0001
<.0001
52.75 55.59
50-60 50-60
5.94 0.73 <.0001
rquartile range; AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease;
ion. *P values based on stratum-adjusted Pearson c2 tests for all categorical row vari-
all continuous/ordinal row variables.
gery c November 2012
TABLE 3. Surgical outcomes after surgical ablation for atrial fibrillation 2005-2010: unmatched data
Outcome Overall (n ¼ 4449 On-CPB (n ¼ 876) Off-CPB (n ¼ 3573) P value*
Operative mortality 0.74 1.71 0.50 .7036
Stroke 0.72 1.26 0.59 .0176
Renal failure 2.45 5.48 1.71 .0001
New pacemaker 1.03 0.80 1.09 .1686
Any complications 16.43 27.97 13.60 <.0001
Perioperative AF 1.55 3.20 1.15 .8025
Deep sternum infection 0.04 0.23 0.00 .0132
Reoperation for bleeding/tamponade 0.99 2.28 0.67 .0127
Pneumonia 1.66 2.74 1.40 .6512
Prolonged ventilation (>24 h) 3.51 6.96 2.66 .1279
Total ventilation durationy (h) <.0001
Median 3.45 5.40 1.40
IQR 0-7.12 3.45-9.70 0-5.25
Postoperative ICU stayy (h) <.0001
Median 26 31.15 25
IQR 21-49 23-70.30 20.05-47
Readmission  30 d 11.22 10.73 11.34 .5551
Intraoperative blood products transfused 5.96 17.58 3.11 <.0001
Discharge medication (warfarin) 75.88 74.43 76.24 .0672
Total length of stay (d)y <.0001
Median 4 6 4
IQR 3-6 5-9 3-6
Data presented as median and IQR or percentages. CPB, Cardiopulmonary bypass; AF, atrial fibrillation; IQR, interquartile range; ICU, intensive care unit. *P values based on
stratum-adjusted Pearson c2 tests for all categorical row variables. yP values based on stratum-adjusted c2 rank-based group mean score statistics for all continuous/ordinal row
variables.
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Dconcomitantly with another cardiac surgical procedure. The
findings of our study suggest that in contrast to a previous
report by Gammie and colleagues,2 no significant change
in the rate of surgical ablation for AF was documented for
concomitant procedure with a use of surgical correction
for AF of 39% to 43% in nonredo, nonemergent patients.
During the study period, 4893 stand-alone procedures
were performed. Most (80%) were performed without the
use of CPB. The data showed excellent safety for both
techniques.
Concomitant Surgical Ablation Procedures
Concomitant surgical ablation for AF is routinely per-
formed in North America; however, there is variability
among cardiac surgeons and centers in the rate these proce-
dures are performed. In an attempt to eliminate variables
that could affect the decision to perform surgical ablation
because of surgical complexity, we excluded patients who
had undergone surgery as redo cardiac surgery or had re-
quired emergent surgery (ie, emergent, emergent salvage,
cardiogenic shock).
The percentage of patients with a history of AF captured
in present study was 11%, similar to that reported by Gam-
mie and colleagues.2 The greatest rates were documented
for patients undergoing MVR, with lower rates of preoper-
ative AF captured for patients with coronary artery disease
undergoingCABG.Although surgical ablation as a concom-
itant procedure is routinely performed, a noted differenceThe Journal of Thoracic and Carwas seen in the rate surgical ablations were performed for
the different types of concomitant procedures, with more
than 60% of patients undergoing MVR also receiving abla-
tion, but only about 30% of patients undergoing CABG or
AVR also receiving surgical correction of AF. The variabil-
ity between procedures is probably related to access to the
left atrium and concerns related to efficacy and increased
morbidity related to the added procedure.
The Heart Rhythm Society (HRS) guidelines8,9 published
consensus indications for concomitant surgical ablation. A
IIA indication (level C evidence) was recommended for
symptomatic patients with all types of AF and a failed class
1 or 3 antiarrhythmic drug. The same recommendation was
given to patients with paroxysmal and persistent AF that
did not fail antiarrhythmic treatment, with an IIB indication
(level C evidence) for patients with long-term persistent AF.
In 2010, the International Society for Minimally Cardio-
thoracic Surgery (ISMICS), published a detailed consensus
statement,7 in which a set of recommendations was given.
In concomitant procedures, a class I (level A evidence)
was given to the efficacy of surgical ablation for AF in re-
storing sinus rhythm both short and long term. It was also
found that surgical ablation is associated with an increased
ejection fraction and improved exercise tolerance test, class
IIA (level A evidence), and a reduced risk of stroke and
thromboembolic events and increased long-term survival,
class IIA (level B evidence). The statement also found
that concomitant surgery was not associated with andiovascular Surgery c Volume 144, Number 5 1055
TABLE 4. Distribution of baseline patient characteristics and outcomes—matched groups
Variable Overall (n ¼ 1708) On-CPB (n ¼ 854) Off-CPB (n ¼ 854) P value*
Demographics
Agey (y) .4568
Mean 59.59 59.48 59.71
IQR 53-67 53-67 53-67
Men 70.90 71.90 69.91 .3653
Risk factors
Body surface areay (m2) .3486
Mean 0.33 0.34 0.33
IQR 0.16-0.52 0.17-0.52 0.16-0.51
Diabetes 17.56 17.92 17.21 .8906
Hypertension 62.30 61.83 62.76 .6897
Peripheral vascular disease 4.10 3.86 4.33 .6255
Cerebrovascular disease 13.76 13.00 14.52 .5618
CHF-NYHA class 4 0.88 1.05 0.70 .6183
Preoperative MI within 21 d 0.35 0.35 0.35 1.0000
Preoperative IABP or inotropes 1.35 1.29 1.41 .8338
Unstable angina without recent MI 0.35 0.59 0.12 .1020
Three diseased coronary vessels 3.28 3.63 2.93 .6598
Urgent status of procedure 3.40 3.98 2.81 .1817
Preoperative AF 36.18 37.70 34.66 .1906
Ejection fractiony .6985
Mean 47.26 47.32 47.20
IQR 50-50 50-50 50-50
Data presented as mean and IQR or percentages. CPB, Cardiopulmonary disease; IQR, interquartile range; CHF, congestive heart failure; NYHA, New York Heart Association;
IABP, intra-aortic balloon pump;MI, myocardial infarction; AF, atrial fibrillation. *P values based on Pearson c2 tests for all categorical row variables. yP values based on c2 rank-
based group mean score statistics for all continuous/ordinal row variables.
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Dincreased risk of operative mortality (level A evidence) and
other perioperative complications, including the need for
a new pacemaker. Both the HRS guidelines and the ISMICS
consensus statements are very important documents,FIGURE 3. Distribution of propensity
1056 The Journal of Thoracic and Cardiovascular Surbecause they agree on the efficacy and safety of the proce-
dures. Surgeons should be aware of these publications when
considering the risks and benefits of concomitant surgical
ablation procedures.score percentiles before matching.
gery c November 2012
FIGURE 4. Distribution of propensity score percentiles after matching.
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DA significant history of AF in patients undergoing cardiac
surgery was an important predictor of mortality both early
and late after surgery.5,6,10 In several recent publications,
it was shown that surgical correction of AF was not
associated with increased operative mortality or morbidity,
even in high-risk patients.11-14 However, some investigators
have found that improved long-term survival was noted com-
paredwith patientswhoseAFwas not treated.6,15Others have
found equal long-term survival compared with patients who
presented for surgery in sinus rhythm.13,14
This relatively new evidence should be reviewed in light
of the increased risk of thromboembolic events andTABLE 5. Patient outcomes—matched groups
Outcome Overall (n ¼ 1708)
Operative mortality (%) 1.23
Stroke (%) 1.00
Dialysis, newly required (%) 0.76
New pacemaker (%) 1.29
Perioperative AF (%) 2.46
Gastrointestinal complication (%) 0.88
Prolonged ventilation (>24 h) (%) 5.27
Reoperation for bleeding/tamponade (%) 1.29
Discharge medication (warfarin) (%) 74.53
Total length of stay (d)
Median 5
IQR 4-8
CPB, Cardiopulmonary bypass; AF, atrial fibrillation; IQR, interquartile range. *P values b
continuous outcomes.
The Journal of Thoracic and Carbleeding events secondary to the use of warfarin therapy.6
A significant decrease in the stroke rate was documented
in patients after the Cox-maze procedure.16,17 The high
success rate of surgical ablation, together with appropriate
management of the left atrial appendage, has improved
our ability to discontinue anticoagulation treatment in
most patients after the Cox-maze procedure. This has
been found to be unrelated to patients’ CHADS score and
is an important benefit when considering adding surgical
ablation for AF.18
When assessing the penetration rate of surgical ablation
for AF during concomitant procedures, it is clear that theOn-CPB (n ¼ 854) Off-CPB (n ¼ 854) P value*
1.52 0.94 .2752
1.29 0.70 .2253
1.05 0.47 .1655
0.82 1.76 .0881
3.04 1.87 .1228
1.05 0.70 .4386
6.56 3.98 .0139
2.22 0.35 .0003
73.89 75.18 .5367
<.0001
6 4
5-9 3-6
ased on McNemar’s tests for categorical outcomes and Wilcoxon signed rank tests for
diovascular Surgery c Volume 144, Number 5 1057
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Dtype of the procedure plays an important role in the decision
to perform surgical ablation. The data presented in the pres-
ent study have demonstrated that fewer than 30% of the pa-
tients undergoing CABG are treated and only slightly more
than 30% of patients undergoing AVR also receive ablation
(Figure 2, Table 1). However, for surgery involving the mi-
tral valve, more than 60% of the patients also underwent ab-
lation when only the mitral valve was treated and more than
50% of the patients did so when MVR was combined with
CABG. From these data, we can assume that the addition of
left atrial atriotomy is amajor negative factor in the decision
making of the surgeon, because of perception that added at-
riotomies could be associated with increased operative risk.
Recently published data might contradict this assumption,
because it has been demonstrated that in patients requiring
CABG or AVR who undergo a Cox-maze procedure, no in-
creased morbidity and mortality was captured.14 It might be
that surgeons are reluctant to perform such an extensive le-
sion set that might be required for patients with nonparox-
ysmal AF. However, this assumption could not be tested
in the present study owing to the inherent limitations of
the STS ACSD.
The results of the present study suggest that a signifi-
cant number of patients are not being treated for AF at
cardiac surgery. The HRS guidelines8,9 and the ISMICS
consensus statement7 both clearly recommend perform-
ing surgical ablation at surgery in appropriate patients.
Education and training on the importance and different
techniques of surgical ablation for AF is very important
to improve patient care. We also need to improve the ev-
idence of concomitant surgical ablation for AF by con-
ducting more well-controlled and balanced prospective
randomized studies.
Stand-Alone Surgical Ablation Procedures
This is the first report using the STS ACSD focusing on
the growth of stand-alone surgical ablation for AF and the
perioperative outcomes of such procedures. During the
study period, a significant increase in the number of
stand-alone procedure with more than 1000 cases per-
formed in 2010. Most stand-alone procedures were per-
formed without the use of CPB and probably using
minimally invasive techniques, such as small thoracotomy
or video-assisted approaches.19,20
In the recent HRS guidelines,8,9 a IIb (level C evidence)
recommendation was made to consider stand-alone surgical
ablation for all types of AF whether or not the patients had
undergone previous attempts at catheter ablation. These
recommendations are very important because stand-alone
surgical ablation was again recognized as a treatment option
for AF. It is important, however, to recognize that the same
guidelines were much more supportive of percutaneous
catheter ablation, with a class I to class IIB indication for
all types of AF-associated conditions.1058 The Journal of Thoracic and Cardiovascular SurIn the present study, we did not attempt to discuss the
long-term success rate of surgical ablation, because the
STS ACSD was not designed to answer such questions.
However, the data provide us with an excellent opportunity
to discuss the safety of stand-alone surgical ablation. The
ACSD is also very limited in helping us to understand the
exact the lesion pattern used during the procedures, because
it was not predefined such that would require surgeons to re-
port accurately on every lesion treated and the ablative tech-
nology used for the different lesions. If the new STS
surgical ablation for AF module is going to gain popularity,
such important and unique data should be available in the
near future (available from: http://www.sts.org/news/sts-
atrial-fibrillation-module-now-available). It is obvious,
however, that in contrast to off-CPB procedures in which
most lesions were confined to the left atrium, in most
stand-alone surgical ablation procedures performed using
on-CPB techniques, a biatrial lesion set was applied
(Table 5). This could have implications regarding the
long-term success rate.21
The outcome of stand-alone surgical ablation for AF is
encouraging. It is also very important to recognize that
off-CPB surgical ablation techniques were introduced
only recently; therefore, the effect of a surgical learning
curve should be considered. The mortality and stroke
rates were about 0.7%, and the rate for a newly required
pacemaker was 1%. The median length of hospital stay
was 4 days, with a relatively low readmission rate at 30
days. It is clear that compared with catheter ablation
for AF, the complication rate was higher. However, pa-
tients undergoing percutaneous catheter ablation for
atrial ablation have had a much lower success rate, ex-
posing patients to additional risk when undergoing the
procedure the second, third, and fourth or more
times.22,23 In a recent report, the complication rate for
catheter ablation was not negligible. Procedural
complications have been reported to affect 1% to 8%
of patients undergoing catheter ablation in experienced
academic centers23,24 and 7% to 10% of Medicare
patients.25 In another report from California, it was
shown that patient complications occurred in 5.1%,
with 30-day mortality of 0.2% and a 30-day stroke/tran-
sient ischemic attack rate of 0.76%.26 The study from
California is important because it compared different
types of centers and operator experience across the state,
not just the best practices.
Patients who underwent surgery using the heart–lung ma-
chine were found to have more comorbidities (Table 2).
This was reflected in the patient outcomes in the non-
matched analysis. After the propensity match analysis,
which included 1708 patients, the safety of the procedures
using CPB was comparable to the safety of those using
off-CPB techniques, with only the duration of ventilation,
reoperation for bleeding, and length of stay significantlygery c November 2012
Ad et al Acquired Cardiovascular Diseasebetter for the off-CPB group. Our experience, and that of
others, suggests very low morbidity when performing
a full Cox-maze procedure for stand-alone AF, suggesting
that the learning curve and experience of the center could
have some affect on the morbidity rate.27-29A
C
DStudy Limitations
The present study used data from the STS ACSD; thus, it
was impossible to describe and assess data related to any
specific association among lesion set, technology, and out-
come. The potential effect of surgeon experience on the rate
of performing concomitant surgical ablation procedures
also could not be assessed.CONCLUSIONS
The present report has demonstrated that surgical abla-
tion for AF as a concomitant procedure is performed in
40% of the patients who present to cardiac surgery with
a history of AF. This rate is somewhat stable compared
with previous report using the same data source.2 How-
ever, the number of patients presenting with AF has actu-
ally increased, which has led to a small decrease in the
percentage of patients undergoing a concomitant surgical
ablation procedure. This has occurred despite recent pub-
lications and guidelines suggesting that surgical ablation
for AF is safe and effective and should be favorably con-
sidered.1,6-9,11-14
In the present study, we also report on a significant in-
crease in the number of stand-alone surgical ablation proce-
dures. The periprocedural outcomes were encouraging,
especially when the significant effect of a learning curve
should be expected. Many of the techniques and devices
have been newly introduced for procedures performed
with or without the use of CPB. Surgeons should also be
aware that major limitations still exist for percutaneous
catheter ablation and need to assist in elevating the discus-
sion about a team approach to deliver better care for patients
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